News

Nanobodies, megapayoff
Enlarge image

BusinessBelgium

Nanobodies, megapayoff

04.10.2012 - Belgian Ablynx secures €8.5m upfront from Merck Inc. for the development of Nanobodies against two targets, one of them yet unknown.

Camelidae antibody developer Ablynx NV (Ghent) has inked a collaboration with US pharma major Merck & Co. Inc (MSD). The companies collaborate primarily to develop and commercialise Nanobody® candidates directed towards a certain voltage-gated ion channel. Merck also acquired the option to do the same for a second, as yet unknown, target. The deal includes a €6.5m upfront payment and another €2m compensation for research funding. With successfully passed regulatory and commercial milestones in addition to secured royalties, Ablynx will be eligible to receive up to €448 million in total. While Ablynx is in charge of the discovery of the Nanobodies, Merck gains the exclusive global rights to market them and is responsible for research, development, manufacturing and commercialisation of any Nanobody® product resulting from the collaboration. 

After Ablynx showed the proof-of-principle in 2011, things are going well for the company despite the withdrawal of US pharma giant Pfizer almost a year ago. Edwin Moses, Chairman and CEO of Ablynx commented on the new deal: "We are delighted to initiate this collaboration with Merck in the area of ion channels, where to date, monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators." Nanobodies® are a novel class of therapeutic proteins based on single-domain, heavy-chain antibody fragments. They link conventional monoclonal antibody advantages like high specificity with the benefits of small molecule drugs like low sensitivity to temperature and pH changes. So far, Ablynx has approximately 25 programmes in the pipeline, and seven Nanobodies at clinical development stage, including partnerships with pharma and biotech companies like Boehringer Ingelheim (cancer, Alzheimer’s), former Merck Serono (osteoarthritis), Novartis, and Merck & Co.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/nanobodies-megapayoff.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products